MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$4K
Net Income
-$44,904K
Net Profit Margin
-1122600.00%
EPS
-$1.92
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
4
2
6
15
Research and development
39,524
36,604
102,670*
28,172
General and administrative
9,576
9,555
10,616
10,687
Other operating (income) loss, net
1,759
1,896
1,497
1,591
Acquired in-process research and development
-
-
16,583*
-
Impairment of long-lived assets
0
-
-721*
0
Total operating expenses
47,341
44,263
127,650
37,268
Loss from operations
-47,337
-44,261
-127,644
-37,253
Interest income, net
2,184
2,194
2,676
3,266
Other income, net
398
17,914
-15,755
-4,859
Impairment of other investments
-
-
0
0
Total other income, net
2,582
20,108
-13,079
-1,593
Net loss
-44,755
-24,153
-140,723
-38,846
Net unrealized gain on marketable securities
-149
-251
41
144
Comprehensive loss
-44,904
-24,404
-140,682
-38,702
Basic EPS
-1.92
-1.1
-8.23
-2.13
Diluted EPS
-1.92
-1.1
-8.23
-2.13
Basic Average Shares
23,364,000
21,876,000
17,093,000*
18,268,000
Diluted Average Shares
23,364,000
21,876,000
17,093,000*
18,268,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$44,904K
(-4.95%↓ Y/Y)
Interest income, net
$2,184K
(-33.33%↓ Y/Y)
Other income, net
$398K
(-66.27%↓ Y/Y)
Net loss
-$44,755K
(-4.85%↓ Y/Y)
Net unrealized gain
on marketable...
-$149K
(-47.52%↓ Y/Y)
Total other income,
net
$2,582K
(-42.06%↓ Y/Y)
Loss from operations
-$47,337K
(-0.42%↓ Y/Y)
Revenue
$4K
(-50.00%↓ Y/Y)
Total operating
expenses
$47,341K
(0.41%↑ Y/Y)
Other operating
(income) loss, net
$1,759K
(265.63%↑ Y/Y)
Research and development
$39,524K
(13.39%↑ Y/Y)
General and
administrative
$9,576K
(-2.15%↓ Y/Y)
Buy us a coffee
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)